top of page

CYCN

Cyclerion Therapeutics

Price

chg

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

low api

52 wk hi

high api

Cash

$41.1 M

Burn Rate (Qtr)

$12.8 M

Mkt Cap

mkt cap api

Avg Volume

volume api

*cash/burn updated:

Q1 '22

Drug Pipeline

Click the button to see the updated pipeline

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Drug Name

Indication

Phase

Event

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

CYCN

BPIQ_Logo_RGB-01.jpg

Company Profile

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company applying neurological insights to discovery, develop, and commercialize innovative medicines for people with serious diseases of the central nervous system (CNS). Lead programs include IW-6463, a pioneering CNS-penetrant sGC stimulator in clinical development for Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Alzheimer's Disease with Vascular pathology (ADv).

Recent Posts

See what the community is saying - click to see full post.

CYCN

bottom of page